Who is the CEO of IMBiologics?

According to the DART company overview, IMBiologics' representative director is 하경식 (name as registered in Korean). The company was founded on 2020-08-04.

Where is IMBiologics listed?

IMBiologics trades on the Korea Exchange KOSDAQ market under the ticker 493280. Its fiscal year ends in December.

What were IMBiologics' latest quarterly results?

In Q3 2026, IMBiologics reported an operating loss of ₩3.4bn. Figures come from reports filed on DART.

Does IMBiologics pay a dividend?

IMBiologics did not pay a cash dividend for fiscal 2025, according to its annual report.

Which companies are in the same industry as IMBiologics?

Under the Korean Standard Industrial Classification recorded on DART, IMBiologics is grouped with 77 other listed companies in research & development. The most covered in Korean news over the past 30 days are SK biopharmaceuticals, Alteogen and D&D Pharmatech.

IMBiologics KRX:493280KOSDAQ

아이엠바이오로직스 · Korean news coverage and regulatory filings, organized.

한국어

Articles, 24h0

Articles, 7 days1

DART filings, 7 days1

Articles tracked14since Sep 11

In Q3 2026, IMBiologics reported an operating loss of ₩3.4bn. IMBiologics (아이엠바이오로직스) appeared in 1 Korean news article and 1 DART filing over the past seven days. Coverage peaked on Nov 2 with 6 articles. The most common catalyst was tech & capacity (3). It was most often mentioned alongside GC Biopharma.

IMBiologics quarterly results separate, KRW

Quarter	Revenue	YoY	Operating profit	Net income
Q3 2026	–	–	−₩3.4bn	−₩3.3bn
Q2 2026	–	–	−₩2.7bn	−₩2.1bn
Q1 2026 check units	₩7.2bn	–	₩2.7bn	₩3.8bn
Q3 2025 check units	₩1.3bn	–	−₩1.1bn	−₩1.7bn
Q2 2025	₩15m	–	−₩2.6bn	−₩10.7bn
Q1 2025	₩10m	–	−₩1.9bn	₩6.9bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

IMBiologics top stories 2 weeks, by number of outlets

1
IM Biologics partners with GC Pharma on bispecific antibodies for autoimmune disease development
2 outlets · 3 articlesFirst report Nov 2 08:14 이데일리PartnershipGC Biopharma
2
IM Biologics signs MTA with GC Pharma on bispecific antibody for autoimmune disease development
2 outlets · 2 articlesFirst report Nov 2 08:20 한국경제GC Biopharma
3
IM Biologics, GC Pharma collaborate on next-generation autoimmune disease therapeutic development
1 outlets · 1 articlesFirst report Nov 2 08:23 뉴스1PartnershipGC Biopharma
4
Multiple new drugs from one antibody...IM Biologics' franchise strategy
1 outlets · 1 articlesFirst report Nov 4 06:07 히트뉴스
5
I'm Biologics posts third-quarter loss of 3.4 billion won…three times higher than year ago
1 outlets · 1 articlesFirst report Nov 13 11:01 비건뉴스

Latest IMBiologics news Korean headlines

Nov 1311:01

I'm Biologics posts third-quarter loss of 3.4 billion won…three times higher than year ago
비건뉴스
Nov 406:07

Multiple new drugs from one antibody...IM Biologics' franchise strategy
히트뉴스
Nov 208:23

IM Biologics, GC Pharma collaborate on next-generation autoimmune disease therapeutic development
뉴스1PartnershipGC Biopharma
Nov 208:20
IM Biologics signs MTA with GC Pharma on bispecific antibody for autoimmune disease development
한국경제GC Biopharma
1 more on this story · 1 outlets
- I'm Biologics concludes MTA for dual antibody treating autoimmune disease with GC Pharma더바이오 · Nov 2 08:31
Nov 208:15
IM Biologics partners with GC Pharma on bispecific antibodies for autoimmune disease development
이데일리PartnershipGC Biopharma
2 more on this story · 2 outlets
- IM Biologics partners with GC Pharma on bispecific antibodies for autoimmune disease development이데일리 · Nov 2 08:14
- IM Biologics shakes hands with GC Pharma on autoimmune disease therapeutic development비즈워치 · Nov 2 09:09
Oct 2611:38

IM Biologics' IMB-101 advances smoothly in global Phase 2 clinical trial
리드경제Clinical trial글로벌테크놀로지
Oct 1806:00

IM Biologics CEO Ha Kyung-sik: 'Clinical trials to decide next year, leap to global new drug company'
뉴스1글로벌테크놀로지
Oct 114:35

아이엠바이오로직스, 유럽피부과학회서 이중항체 연구 3건 공개
뉴스1
Oct 114:18
아이엠바이오로직스, EADV서 ‘IMB-101’ 연구결과 3건 발표
이데일리
1 more on this story · 1 outlets
- 아이엠바이오로직스, EADV서 ‘IMB-101’ 연구결과 3건 발표이데일리 · Oct 1 14:19
Sep 2116:23

아이엠바이오로직스, AI로 신약후보 압축···효율성 입증 과제
시사저널e

Articles per day 2 weeks

113

Company profile

CEO: 하경식
Industry: Research & development
Founded: 2020-08-04
Fiscal year-end: December
Head office: 경기도 수원시
Website: imbiologics.com
Quotes & chart: Naver Securities (Korean)

From the DART company overview.

Major shareholders latest 5%+ report per holder

Korea 5% stake disclosures

하경식36.49%
신한벤처투자5.28%

Each holder's most recent 5% ownership report on DART; names as filed in Korean.

Same industry Research & development

All in industry

Company	Latest quarter op. profit	Articles 30d
SK biopharmaceuticals	–	324
Alteogen	–	255
D&D Pharmatech	−₩13.6bn	72
LigaChem Biosciences	−₩50.4bn	69
Curocell	−₩7.7bn	51
HLB Pharmaceutical	₩847m	44
SillaJen	–	44
Onconic Therapeutics	–	43

Compare IMBiologics side by side with these companies

IMBiologics DART filings

Nov 1216:32

Quarterly report (September 2026)
Other
Oct 1914:36

Corporate briefing (IR) held
Other
Sep 1017:11

Large share holding status report (abbreviated form)
Ownership reports

Catalysts 2 weeks

Tech & capacity3

Mentioned alongside 2 weeks

1 GC BiopharmaKOSPI 6

IMBiologics FAQ

Who is the CEO of IMBiologics?: According to the DART company overview, IMBiologics' representative director is 하경식 (name as registered in Korean). The company was founded on 2020-08-04.
Where is IMBiologics listed?: IMBiologics trades on the Korea Exchange KOSDAQ market under the ticker 493280. Its fiscal year ends in December.
What were IMBiologics' latest quarterly results?: In Q3 2026, IMBiologics reported an operating loss of ₩3.4bn. Figures come from reports filed on DART.
Does IMBiologics pay a dividend?: IMBiologics did not pay a cash dividend for fiscal 2025, according to its annual report.
Which companies are in the same industry as IMBiologics?: Under the Korean Standard Industrial Classification recorded on DART, IMBiologics is grouped with 77 other listed companies in research & development. The most covered in Korean news over the past 30 days are SK biopharmaceuticals, Alteogen and D&D Pharmatech.